AstraZeneca Pharma reported 39% revenue growth in Q3 FY26, driven by strong traction across oncology and biopharma portfolios, even as EBITDA declined sharply and margins narrowed year-on-year.
AstraZeneca Pharma reported 39% revenue growth in Q3 FY26, driven by strong traction across oncology and biopharma portfolios, even as EBITDA declined sharply and margins narrowed year-on-year.